ZOONOZIS - VECTOR-BORNE DISEASES / REVIEW PAPER
ROLE OF VlsE/C6 ANTIGEN AS A MARKER FOR EARLY LYME BORRELIOSIS
DIAGNOSIS AND MONITORING THE EFFECTIVENESS OF ITS TREATMENT
1
Euroimmun Polska Sp. z o.o., Poland
Submission date: 2017-03-30
Final revision date: 2017-04-09
Acceptance date: 2017-04-24
Publication date: 2017-07-28
Health Prob Civil. 2017;11(2):87-92
KEYWORDS
TOPICS
ABSTRACT
Diagnosing Lyme borreliosis, despite years of standardization, continues to encounter
difficulties. They result primarily from the lack of a good marker of active infection and one
helpful in assessing the effectiveness of the treatment. So far, a certain diagnosis of Lyme
borreliosis can be made only in a patient with erythema migrans (EM). Unfortunately, this
symptom occurs only in some patients. According to the recommendations of the Polish
Society of Epidemiologists and Doctors of Infectious Diseases, the effectiveness of treatment
is determined by the disappearance of clinical symptoms. For this reason, for years, we have
been looking for highly sensitive and diagnostically specific laboratory markers. These
would allow for rapid identification of fresh infections with Borrelia spirochetes as well
as simple monitoring of treatment efficacy. According to many of the recently published
publications, the solution to the second of the presented problems may be the measurement
of IgG antibodies to the surface antigen of Borrelia burgdorferi s.l. VlsE / C6.
difficulties. They result primarily from the lack of a good marker of active infection and one
helpful in assessing the effectiveness of the treatment. So far, a certain diagnosis of Lyme
borreliosis can be made only in a patient with erythema migrans (EM). Unfortunately, this
symptom occurs only in some patients. According to the recommendations of the Polish
Society of Epidemiologists and Doctors of Infectious Diseases, the effectiveness of treatment
is determined by the disappearance of clinical symptoms. For this reason, for years, we have
been looking for highly sensitive and diagnostically specific laboratory markers. These
would allow for rapid identification of fresh infections with Borrelia spirochetes as well
as simple monitoring of treatment efficacy. According to many of the recently published
publications, the solution to the second of the presented problems may be the measurement
of IgG antibodies to the surface antigen of Borrelia burgdorferi s.l. VlsE / C6.
REFERENCES (70)
1.
Pancewicz SA, Garlicki AM, Moniuszko-Malinowska A, Zajkowska J, Kondrusik M, Grygorczuk S, et al.
2.
Polish Society of Epidemiology and Infectious Diseases. Diagnosis and treatment of tick-borne diseases.
3.
recommendations of the Polish Society of Epidemiology and Infectious Diseases. Przegl Epidemiol. 2015;.
5.
Zachorowania na wybrane choroby zakaźne w Polsce od 1 stycznia do 31 grudnia 2016 r. oraz.
6.
w porównywalnym okresie 2015 r, Narodowy Instytut Zdrowia Publicznego – Państwowy Zakład Higieny,.
7.
Zakład Epidemiologii, Departament Zapobiegania oraz Zwalczania Zakażeń i Chorób Zakaźnych u Ludzi GIS.
10.
Chmielewski T, Dunaj J, Gołąb E, Gut W, Horban A, Pancewicz S, et al. „Diagnostyka laboratoryjna chorób.
11.
odkleszczowych” Rekomendacje Grupy Roboczej: Krajowa Izba Diagnostów Laboratoryjnych, Narodowy Instytut Zdrowia Publicznego - Państwowy Zakład Higieny, Konsultant Krajowy w dziedzinie chorób.
12.
zakaźnych, Klinika Chorób Zakaźnych i Neuroinfekcji Uniwersytet Medyczny w Białymstoku, Polskie.
13.
Towarzystwo Wirusologiczne, Krajowa Izba Diagnostów Laboratoryjnych, Warszawa 2014, p. 20 [Internet].
16.
Norris SJ. vls Antigenic Variation Systems of Lyme Disease Borrelia: Eluding Host Immunity through both.
17.
Random, Segmental Gene Conversion and Framework Heterogeneity. Microbiol Spectr. 2014 Dec;2(6), doi:.
19.
Bubeck-Martinez S. Immune evasion of the Lyme disease spirochetes. Front Biosci. 2005 Jan 1;10:873-8.
20.
Eicken C, Sharma V, Klabunde T, Lawrenz MB, Hardham JM, Norris SJ, et al. Crystal structure of Lyme disease variable surface antigen VlsE of Borrelia burgdorferi. J Biol Chem. 2002 Jun 14; 277(24): 21691-6.
21.
Sung SY, McDowell JV, Marconi RT. Evidence for the contribution of point mutations to VlsE variation and.
22.
for apparent constraints on the net accumulation of sequence changes in VlsE during infection with Lyme.
24.
Labandeira-Rey M, Baker E, Skare JT. Decreased infectivity in Borrelia burgdorferi strain B31 is associated.
26.
Purser JE, Norris SJ. Correlation between plasmid content and infectivity in Borrelia burgdorferi. Proc. Natl.
28.
Rogovskyy AS, Bankhead T. Variable VlsE is critical for host reinfection by the Lyme disease spirochete. PLoS.
30.
Goettner G, Schulte-Spechtel U, Hillermann R, Liegl G, Wilske B, Fingerle V. Improvement of Lyme borreliosis.
31.
serodiagnosis by a newly developed recombinant immunoglobulin G (IgG) and IgM line immunoblot assay.
32.
and addition of VlsE and DbpA homologues. J Clin Microbiol. 2005 Aug; 43(8): 3602-9.
33.
Schulte-Spechtel U, Lehnert G, Liegl G, Fingerle V, Heimerl C, Johnson BJ, et al. Significant improvement.
34.
of the recombinant Borrelia-specific immunoglobulin G immunoblot test by addition of VlsE and a DbpA.
35.
homologue derived from Borrelia garinii for diagnosis of early neuroborreliosis. J Clin Microbiol. 2003 Mar;.
37.
Wilske B. Epidemiology and diagnosis of Lyme borreliosis. Ann Med. 2005; 37(8): 568-79.
38.
Liang FT, Steere AC, Marques AR, Johnson BJ, Miller JN, Philipp MT. Sensitive and specific serodiagnosis.
39.
of Lyme disease by enzyme-linked immunosorbent assaywith a peptide based on an immunodominant.
40.
conserved region of Borrelia burgdorferi VlsE. J Clin Microbiol. 1999 Dec; 37(12): 3990-6.
41.
Liang FT, Philipp MT. Analysis of antibody response to invariable regions of VlsE, the variable surface antigen.
43.
Liang FT, Philipp MT. Epitope mapping of the immunodominant invariable region of Borrelia burgdorferi.
45.
Embers ME, Jacobs MB, Johnson BJ, Philipp MT. Dominant epitopes of the C6 diagnostic peptide of Borrelia.
46.
burgdorferi are largely inaccessible to antibody on the parent VlsE molecule. Clin Vaccine Immunol. 2007.
48.
Zajkowska JM, Kondrusik M, Pancewicz SA, Grygorczuk S, Jamiołkowski J, Stalewska J. Comparison of test.
49.
with antigen VlsE (C6) with tests with recombinant antigens in patients with Lyme borreliosis. Pol Merkur.
51.
Cinco M, Murgia R. Evaluation of the C6 enzyme-linked immunoadsorbent assay for the serodiagno.
53.
Lyme borreliosis in north-eastern Italy. New Microbiol. 2006 Apr; 29(2): 139-41.Johnson B. Advantages and limitations of testing for antibodies to B.burgdorferi sensu stricto. IX International Conference on Lyme Borreliosis and Other Tick Borne Diseases. August 18-22, 2002, NY. Abstracts.
54.
Fingerle V, Schulte-Spechtel U, Levin A. i wsp.: Evaluation of an ELISA based on the C6 peptide of VlsE for.
55.
diagnosis of early neuroborreliosis. IX International Conference on Lyme Borreliosis and Other Tick Borne.
57.
Stanek G, Lusa L, Ogrinc K, Markowicz M, Strle F. Intrathecally produced IgGand IgM antibodies to recombinant VlsE, VlsE peptide, recombinant OspC and whole cell extracts in the diagnosis of Lyme neuroborreliosis. Med Microbiol Immunol. 2014 Apr; 203(2): 125-32.
58.
van Burgel ND, Brandenburg A, Gerritsen HJ, Kroes AC, van Dam AP. High sensitivity and specificity of the.
59.
C6-peptide ELISA on cerebrospinal fluid in Lyme neuroborreliosis patients. Clin Microbiol Infect. 2011 Oct;.
61.
Philipp MT, Bowers LC, Fawcett PT, Jacobs MB, Liang FT, Marques AR, et al. Antibody response to IR6,.
62.
a conserved immunodominant region of the VlsE lipoprotein, wanes rapidly after antibiotic treatment of.
63.
Borrelia burgdorferi infection in experimental animals and in humans. J Infect Dis. 2001 Oct 1; 184(7): 870-8.
64.
Levy SA, O’Connor TP, Hanscom JL, Shields P, Lorentzen L, Dimarco AA. Quantitative measurement of C6.
65.
antibody following antibiotic treatment of Borrelia burgdorferi antibody-positive nonclinical dogs. Clin.
67.
Marangoni A, Sambri V, Accardo S, Cavrini F, Mondardini V, Moroni A, et al. A decrease in the immunoglobulin G antibody response against the VlsE protein of Borrelia burgdorferi sensu lato correlates with the resolution of clinical signs in antibiotic-treated patients with early Lyme disease. Clin Vaccine Immunol. 2006 Apr; 13(4): 525-9.
68.
Fleming RV, Marques AR, Klempner MS, Schmid CH, Dally LG, Martin DS, el al. Pre-treatment and post.
69.
treatment assesment of the c(6) test in patients with persistent symptoms and history of Lyme borreliosis.
Share
RELATED ARTICLE
| eISSN: | 2354-0265 |
| ISSN: | 2353-6942 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
